Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
BACKGROUND: The treatment of non-small cell lung cancer (NSCLC) has undergone changes that have improved the prognosis of patients. With the advent of immunotherapy, it has been possible to prolong significantly the overall and progression-free survival as well as quality of life. Nevertheless, its...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2023-09-01
|
| Series: | World Cancer Research Journal |
| Subjects: | |
| Online Access: | https://www.wcrj.net/wp-content/uploads/sites/5/2023/09/e2660.pdf |
| _version_ | 1797672311092936704 |
|---|---|
| author | R. Riera-Sala A. Ibarra-Morales J. Guzmán-Casta R. Medrano-Guzmán A. Dip-Borunda A. Martin-Aguilar R. Grajales-Álvarez R. Correa-Cano K. Elvira-Fabián C. Sánchez-Ríos A. Orzuna-Vázquez J. Rovelo-Lima L. Martínez-Barrera J. Rodríguez-Cid J. Alatorre-Alexander |
| author_facet | R. Riera-Sala A. Ibarra-Morales J. Guzmán-Casta R. Medrano-Guzmán A. Dip-Borunda A. Martin-Aguilar R. Grajales-Álvarez R. Correa-Cano K. Elvira-Fabián C. Sánchez-Ríos A. Orzuna-Vázquez J. Rovelo-Lima L. Martínez-Barrera J. Rodríguez-Cid J. Alatorre-Alexander |
| author_sort | R. Riera-Sala |
| collection | DOAJ |
| description | BACKGROUND: The treatment of non-small cell lung cancer (NSCLC) has undergone changes that have improved the prognosis of patients. With the advent of immunotherapy, it has been possible to prolong significantly the overall and progression-free survival as well as quality of life. Nevertheless, its use represents clinical challenges which may turn into adverse events, such as progression and pseudo-progression, which are uncontrolled and often deleterious immune responses that simulate tumoral progression, generate worsening of symptoms and performance status of patients and even may lead to non-cancer related death of patients.
MATERIALS AND METHODS: We assessed 128 records (clinical trials, reports, meta-analyses) in order to provide an updated review of the treatment of NSCLC, current definitions proposed for pseudo and hyperprogression (which are not homogeneous so far), incidence, theories about their physiopathogenesis, importance of making a judicious diagnostic workup, imaging criteria as well as biochemical markers in order to predict their appearance, concluding with a brief discussion about the topic addressed.
CONCLUSIONS: Since there is no definition or standardized diagnostic and imaging criteria, these entities are a topic of major interest in the area of oncologic immunotherapy, for which the following review has been generated. |
| first_indexed | 2024-03-11T21:28:06Z |
| format | Article |
| id | doaj.art-a7c5e98aa75a406d91e89de7ccbf0513 |
| institution | Directory Open Access Journal |
| issn | 2372-3416 |
| language | English |
| last_indexed | 2024-03-11T21:28:06Z |
| publishDate | 2023-09-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | World Cancer Research Journal |
| spelling | doaj.art-a7c5e98aa75a406d91e89de7ccbf05132023-09-27T15:35:32ZengVerduci EditoreWorld Cancer Research Journal2372-34162023-09-011010.32113/wcrj_20239_26602660Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancerR. Riera-Sala0A. Ibarra-Morales1J. Guzmán-Casta2R. Medrano-Guzmán3A. Dip-Borunda4A. Martin-Aguilar5R. Grajales-Álvarez6R. Correa-Cano7K. Elvira-Fabián8C. Sánchez-Ríos9A. Orzuna-Vázquez10J. Rovelo-Lima11L. Martínez-Barrera12J. Rodríguez-Cid13J. Alatorre-Alexander14Department of Thoracic Malignancies, Clinical Oncologist, Fellow in Thoracic Oncology, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoClinical Oncology Resident, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoClinical Oncologist, Fellow in Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, MexicoSurgical Oncologist, Headmaster of the UMAE Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoClinical Oncologist, Head of Medical Oncology at Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoDepartment of Genitourinary Tumors, Clinical Oncologist, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoDepartment of Breast Cancer, Clinical Oncologist, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoClinical Oncology Resident, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoGeneral Physician, Hospital ABC Santa Fé, Mexico City, MexicoPulmonologist, Fellow in Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, MexicoClinical Oncology Resident, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City, MexicoSurgical Oncologist, Hospital Star Médica, Lomas Verdes, MexicoClinical Oncologist, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, MexicoClinical Oncologist and Head of Medical Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, MexicoHead of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, MexicoBACKGROUND: The treatment of non-small cell lung cancer (NSCLC) has undergone changes that have improved the prognosis of patients. With the advent of immunotherapy, it has been possible to prolong significantly the overall and progression-free survival as well as quality of life. Nevertheless, its use represents clinical challenges which may turn into adverse events, such as progression and pseudo-progression, which are uncontrolled and often deleterious immune responses that simulate tumoral progression, generate worsening of symptoms and performance status of patients and even may lead to non-cancer related death of patients. MATERIALS AND METHODS: We assessed 128 records (clinical trials, reports, meta-analyses) in order to provide an updated review of the treatment of NSCLC, current definitions proposed for pseudo and hyperprogression (which are not homogeneous so far), incidence, theories about their physiopathogenesis, importance of making a judicious diagnostic workup, imaging criteria as well as biochemical markers in order to predict their appearance, concluding with a brief discussion about the topic addressed. CONCLUSIONS: Since there is no definition or standardized diagnostic and imaging criteria, these entities are a topic of major interest in the area of oncologic immunotherapy, for which the following review has been generated.https://www.wcrj.net/wp-content/uploads/sites/5/2023/09/e2660.pdfpseudoprogressionhyperprogressionimmunotherapylung cancer |
| spellingShingle | R. Riera-Sala A. Ibarra-Morales J. Guzmán-Casta R. Medrano-Guzmán A. Dip-Borunda A. Martin-Aguilar R. Grajales-Álvarez R. Correa-Cano K. Elvira-Fabián C. Sánchez-Ríos A. Orzuna-Vázquez J. Rovelo-Lima L. Martínez-Barrera J. Rodríguez-Cid J. Alatorre-Alexander Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer World Cancer Research Journal pseudoprogression hyperprogression immunotherapy lung cancer |
| title | Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| title_full | Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| title_fullStr | Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| title_full_unstemmed | Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| title_short | Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| title_sort | pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer |
| topic | pseudoprogression hyperprogression immunotherapy lung cancer |
| url | https://www.wcrj.net/wp-content/uploads/sites/5/2023/09/e2660.pdf |
| work_keys_str_mv | AT rrierasala pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT aibarramorales pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT jguzmancasta pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT rmedranoguzman pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT adipborunda pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT amartinaguilar pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT rgrajalesalvarez pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT rcorreacano pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT kelvirafabian pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT csanchezrios pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT aorzunavazquez pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT jrovelolima pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT lmartinezbarrera pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT jrodriguezcid pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer AT jalatorrealexander pseudoprogressionandhyperprogressionsecondarytoimmunotherapyinlungcancer |